Detail of "73590-85-9"

CAS Number:
73590-85-9
Name:
1H-Benzimidazole,6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-
Superlist Name:
Ufiprazole
Molecular Structure:
Formula:
C₁₇H₁₉N₃O₂S
Molecular Weight:
329.42
Synonyms:
1H-Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]- (9CI);2-[[(3,5-Dimethyl-4-methoxy-2-pyridyl)methyl]thio]-5-methoxy-1H-benzimidazole;2-[[(3,5-Dimethyl-4-methoxy-2-pyridyl)methyl]thio]-5-methoxybenzimidazole;5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole;5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]-1H-benzimidazole;H 168/22;Omeprazole sulfide;Pyrmetazole;
Density:
1.28 g/cm³
Boiling Point:
539.7 °C at 760 mmHg
Flash Point:
280.2 °C

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Supplier Location
Supplier Location
- China (Mainland)(20)
- India(7)
- United Kingdom(1)
- United States(1)
Business Type
Business Type
- Lab/Research institutions(3)
- Manufacturers(2)
- Trading Company(20)
Certificates
Certificates
- ISO(2)
- Production License(1)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

Inhibition of gastric potassium-proton-dependent ATPase by acid-activated 2-[(2-pyridylmethyl)sulfinyl]benzimidazole products: Inhibition of gastric potassium-proton-dependent ATPase by acid-activated 2-[(2-pyridylmethyl)sulfinyl]benzimidazole products. Beil, Winfried; Hannemann, Helga; Maedge, Simone; Sewing, Karl Friedrich (Abt. Allg. Pharmakol., Med. 9000-83-3 and 73590-58-6 are also occured in this study. Hochsch. Hannover, Hannover D-3000, Fed. Rep. Ger.). Eur. J. Pharmacol., 133(1), 37-45 (English) 1987. CODEN: EJPHAZ. ISSN: 0014-2999. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The inhibitory effects of timoprazole [57237-97-5], omeprazole [73590-58-6], and metabolites of these 2 benzimidazoles were studied in different in vitro test systems in order to characterize the metabolites of substituted benzimidazoles originating from acid activation. Acidification of timoprazole and omeprazole to pH 1.0 markedly increased the inhibitory potency on gastric K+/H+-ATPase. The timoprazole-derived tetracyclic thiol and radical were found to be equally or more potent on the K+/H+-ATPase than the mother compds. dissolved at pH 1.0. Kinetic studies with omeprazole sulfide [73590-85-9] revealed a competitive inhibition of the K+/H+-ATPase with respect to K+. The mercaptan dithiothreitol reversed the inhibitory effect of omeprazole, acidified timoprazole, and the timoprazole-derived radical in the parietal cell and K+/H+-ATPase prepn. In contrast, the inhibitory effect of omeprazole sulfide and the timoprazole-derived thiol [97266-62-1] could not be reversed by dithiothreitol. Wash-out expts. indicated that acidified timoprazole and the tetracyclic compds. interact irreversibly with the K+/H+-ATPase, which contrasts with the properties of timoprazole in the parietal cell prepn. It is concluded from these data that neither the tetracyclic compds. nor the sulfide act as the active principle of substituted benzimidazoles in the parietal cell prepn. .

Determination of omeprazole and metabolites in plasma and urine by liquid chromatography: Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. Lagerstroem, Per Olof; Persson, Bengt Arne (Dep. Anal. Chem., AB Haessle, Molndal S-431 83, Swed.). J. Chromatogr., 309(2), 347-56 (English) 1984. CODEN: JOCRAM. ISSN: 0021-9673. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Omeprazole (I) [73590-58-6], a substituted benzimidazole and a new gastric acid inhibitor, was detd. in plasma and urine, together with 3 of its metabolites: the sulfide [73590-85-9], the sulfone [88546-55-8] and the hydroxy compd. [92340-57-3]. The methods comprised extn. from the biol. materials with CH2Cl2, followed either by direct injection of the ext. onto a normal-phase liq. chromatog. column or evapn., dissoln., and injection onto a reversed-phase system. The compds. were detected by UV spectrometry. The abs. recoveries obtained were mostly >95%. The min. determinable concn. of omeprazole was 20 nmol/L plasma (relative std. deviation 10-15%) and 50 nmol/L in urine. The metabolites could also be detd. at the same levels.

Detail of "73590-85-9"

1H-Benzimidazole,6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.73590-85-9 ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

CAS No.73590-85-9 Ufiprazole

Reference